![](https://spiegellab.yale.edu/sites/default/files/ancreading_newspaper2.jpg)
November 1, 2013
Congratulations to Phil on his work on developing a liver-targeting mitochondrial uncoupler that can serve as a potential therapeutic agent for hypertriglyceridemia, non-alcoholic fatty liver disease, and insulin resistance, in collaboration with the Shulman Group at Yale. Read about it here: Cell Metabolism